Published in Melanoma Res on December 01, 2012
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr (2013) 1.13
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med (2013) 1.02
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology (2014) 0.91
Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol (2016) 0.76
Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol (2014) 0.76
The biology of uveal melanoma. Cancer Metastasis Rev (2017) 0.75
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer (2016) 0.75
The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat (2016) 0.75
The genetics of uveal melanoma: current insights. Appl Clin Genet (2016) 0.75
Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management. Oncologist (2013) 0.75
Role of cytogenetics in management of uveal melanoma. Arch Ophthalmol (2008) 2.73
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol (2003) 1.74
The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol (2010) 1.38
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res (2011) 1.22
Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg (2007) 1.00
Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol (2010) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol (2011) 0.97
Laparoscopic adrenalectomy: indications and technique. Curr Surg (2004) 0.96
Uveal melanoma trapped in the temple of doom. Am J Ophthalmol (2012) 0.92
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother (2011) 0.91
Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2008) 0.91
Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. AJR Am J Roentgenol (2011) 0.90
Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford) (2013) 0.90
Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res (2005) 0.90
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol (2002) 0.88
High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology (2009) 0.88
Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol (2011) 0.87
The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol (2010) 0.86
Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res (2014) 0.85
Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol (2007) 0.85
An introduction to laparoscopic gastric resection. Curr Surg (2004) 0.85
Malignant melanoma of the gallbladder: a report of two cases and review of the literature. J Gastrointest Surg (2007) 0.84
Current status of laparoscopic appendectomy. Curr Surg (2004) 0.83
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer (2010) 0.83
Laparoscopic fundoplication. Curr Surg (2004) 0.83
Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol (2011) 0.82
Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol (2016) 0.82
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res (2007) 0.82
Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother (2002) 0.81
Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J (2006) 0.80
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother (2011) 0.80
Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother (2009) 0.79
Calculation of survival of patients with stage III melanoma. J Clin Oncol (2005) 0.79
A valid method of laparoscopic simulation training and competence assessment. J Surg Res (2003) 0.78
Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol (2014) 0.78
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol (2011) 0.78
Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother (2003) 0.78
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77
Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res (2013) 0.77
The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs (2013) 0.77
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? Rev Recent Clin Trials (2016) 0.77
Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am (2008) 0.76
Laparoscopic common bile duct exploration. Curr Surg (2004) 0.75
Laparoscopic cholecystectomy--technical considerations. Curr Surg (2005) 0.75
Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs (2015) 0.75
Minimally invasive parathyroidectomy and parathyroid imaging. Curr Surg (2005) 0.75
Altered drainage patterns in patients with melanoma and previous axillary dissection. J Dermatol (2013) 0.75
Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater. JOP (2010) 0.75
Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments? Semin Oncol (2010) 0.75
Impact of malignant disease on young adults. Semin Oncol (2009) 0.75
Mind the BAP. Pigment Cell Melanoma Res (2011) 0.75
The Last Chapter. Semin Oncol (2015) 0.75
The minimally invasive surgical approach to achalasia: a new standard of care? Curr Surg (2005) 0.75